ASX ANNOUNCEMENT
29 FEBRUARY 2024

First Participant Dosed in Phase 1 Pancreatic Imaging Study of 68Ga-Trivehexin (RAD 301)

- *First Pancreatic Cancer participant dosed at the Montefiore Medical Center, New York, USA*
- *Phase I study of 9 participants is designed to assess the safety and dosimetry of RAD 301*
- *A total of 99 patients have been previously imaged with RAD 301 under compassionate use or as part of an Investigator-Initiated Study, with no arising safety issues reported*.*

Sydney, Australia – 29 February 2024 – Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that the first patient was dosed with 68Ga-Trivehexin (RAD 301), a diagnostic radiopharmaceutical targeting αvβ6 integrin, for the detection of lesions in patients with Pancreatic Ductal Adenocarcinoma (PDAC). In May 2023, the FDA granted Radiopharm with an Orphan Drug Designation (ODD) for RAD 301 in pancreatic cancer.

"We are very excited by the progress being made on our RAD 301 clinical program with the dosing of the first participant in this imaging study," said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. "Current imaging standards of care for the detection of Pancreatic Ductal Adenocarcinoma (PDAC) have significant limitations, making it one of the highest areas of unmet medical need. As such, it poses a major challenge for healthcare providers imaging PDAC patients. We are delighted to take one major step forward in potentially providing all patients with cancers expressing αvβ6-integrin an alternative and much-needed imaging option."

About the 68Ga-Trivehexin (RAD 301) Phase 1 Clinical Trial
The Phase I clinical trial is currently being conducted at the Montefiore Medical Center, Albert Eistein College of Medicine, NY, USA. The study will assess the safety, radiation dosimetry and imaging characteristics of RAD 301 in patients with advanced PDAC.

About 68Ga-Trivehexin (RAD 301)
Trivehexin is a peptide-based molecule that targets αvβ6-integrin, a cellular marker for tumour invasion and metastatic growth, the expression of which correlates with decreased survival in several carcinomas. The αvβ6-integrin receptor is found in high density on most pancreatic carcinoma cells, making it an attractive diagnostic and therapeutic target.

*Reference: Quigley, N.G., Czech, N., Sendt, W. et al. PET/CT imaging of pancreatic carcinoma targeting the "cancer integrin" αvβ6. Eur J Nucl Med Mol Imaging 48, 4107–4108 (2021).

Das SS, Sen IB, Malik D, Thakral P, Targeted imaging of αvβ6-integrin in patients of Head and Neck Squamous Cell Carcinoma and Pancreatic Ductal Adenocarcinoma with 68Ga-Trivehexin PET/CT scan and correlation with immunohistochemistry- a pilot study. Eur J Nucl Med Mol Imaging 2023:50;S351.

ASX ANNOUNCEMENT
29 FEBRUARY 2024

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm has been listed on ASX (RAD) since November 2021. The company has a pipeline of six distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the world's leading universities and institutes. The pipeline has been built based on the potential to be first-to-market or best-in-class. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumour cancers including breast, kidney and brain. Learn more at Radiopharmtheranostics.com.

Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.

For more information:

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
Twitter – https://twitter.com/TeamRadiopharm
Linked In – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/